

Herbert K Lyerly

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2424806/publications.pdf>

Version: 2024-02-01

350
papers

17,473
citations

15001

68
h-index

21843

118
g-index

362
all docs

362
docs citations

362
times ranked

20829
citing authors

#	ARTICLE	IF	CITATIONS
1	HSP90-Specific nIR Probe Identifies Aggressive Prostate Cancers: Translation from Preclinical Models to a Human Phase I Study. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 217-226.	1.9	2
2	Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity. , 2022, 10, e003717.		27
3	Trastuzumab/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis. <i>JCI Insight</i> , 2022, 7, .	2.3	14
4	Sensitizing immune unresponsive colorectal cancers to immune checkpoint inhibitors through MAVS overexpression. , 2022, 10, e003721.		6
5	Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity. <i>Molecular Therapy - Oncolytics</i> , 2022, 25, 174-188.	2.0	5
6	Gene expression signatures of individual ductal carcinoma in situ lesions identify processes and biomarkers associated with progression towards invasive ductal carcinoma. <i>Nature Communications</i> , 2022, 13, .	5.8	12
7	Blood microbiota diversity determines response of advanced colorectal cancer to chemotherapy combined with adoptive T cell immunotherapy. <i>Oncolmmunology</i> , 2021, 10, 1976953.	2.1	13
8	Cancer vaccines: the importance of targeting oncogenic drivers and the utility of combinations with immune checkpoint inhibitors. <i>Oncotarget</i> , 2021, 12, 1-3.	0.8	2
9	Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti-“PD-1 Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 2481-2493.	3.2	33
10	Targeting the glucagon receptor signaling pathway as a novel strategy to counteract PI3K inhibitor induced hyperglycemia while sustaining tumor PI3K inhibition. <i>Leukemia and Lymphoma</i> , 2021, 62, 1761-1764.	0.6	1
11	HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase. <i>Molecular Cancer Research</i> , 2021, 19, 1699-1711.	1.5	5
12	Abstract 1557: Intratumoral plasmid IL-12 enhanced the systemic anti-tumor effect of anti-PD-1 antibody in triple-negative breast cancer. , 2021, , .		0
13	Exposure to low-dose ambient fine particulate matter PM2.5 and Alzheimer’s disease, non-Alzheimer’s dementia, and Parkinson’s disease in North Carolina. <i>PLoS ONE</i> , 2021, 16, e0253253.	1.1	38
14	A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop. <i>Clinical Cancer Research</i> , 2021, 27, 5472-5481.	3.2	4
15	Changes in Peripheral Blood Regulatory T Cells and IL-6 and IL-10 Levels Predict Response of Pediatric Medulloblastoma and Germ Cell Tumors With Residual or Disseminated Disease to Craniospinal Irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 479-490.	0.4	3
16	Serial assessment of circulating T lymphocyte phenotype and receptor repertoire during treatment of non-muscle invasive bladder cancer with adoptive T cell immunotherapy. <i>American Journal of Cancer Research</i> , 2021, 11, 1709-1718.	1.4	1
17	Miniaturized Intracavitary Forward-Looking Ultrasound Transducer for Tissue Ablation. <i>IEEE Transactions on Biomedical Engineering</i> , 2020, 67, 2084-2093.	2.5	15
18	Adoptive immunotherapy with autologous T-cell infusions reduces opioid requirements in advanced cancer patients. <i>Pain</i> , 2020, 161, 127-134.	2.0	15

#	ARTICLE	IF	CITATIONS
19	Sperm DNA methylation altered by THC and nicotine: Vulnerability of neurodevelopmental genes with bivalent chromatin. <i>Scientific Reports</i> , 2020, 10, 16022.	1.6	33
20	Uterine Cancer Mortality in White and African American Females in Southeastern North Carolina. <i>Journal of Environmental and Public Health</i> , 2020, 2020, 1-9.	0.4	3
21	Long-term survival of patients with stage III colon cancer treated with VRP-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratio. , 2020, 8, e001662.		28
22	Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and \pm PD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4670-4681.	3.2	31
23	Heat shock protein 90-targeted photodynamic therapy enables treatment of subcutaneous and visceral tumors. <i>Communications Biology</i> , 2020, 3, 226.	2.0	18
24	IL26, a Noncanonical Mediator of DNA Inflammatory Stimulation, Promotes TNBC Engraftment and Progression in Association with Neutrophils. <i>Cancer Research</i> , 2020, 80, 3088-3100.	0.4	14
25	HER2-LAMP vaccines effectively traffic to endolysosomal compartments and generate enhanced polyfunctional T cell responses that induce complete tumor regression. , 2020, 8, e000258.		9
26	An age-independent gene signature for monitoring acute rejection in kidney transplantation. <i>Theranostics</i> , 2020, 10, 6977-6986.	4.6	9
27	Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting. <i>Clinical Cancer Research</i> , 2020, 26, 4743-4747.	3.2	0
28	Patient-Reported Outcomes in Oncology Clinical Trials: Stakeholder Perspectives from the Accelerating Anticancer Agent Development and Validation Workshop 2019. <i>Oncologist</i> , 2020, 25, 819-821.	1.9	7
29	DC-CIK as a widely applicable cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 601-607.	1.4	28
30	Abstract 904: Stimulation and expansion of oncogene-reactive tumor infiltrating T cells through combined Ad-HER2 \hat{r} 16 vaccination and anti-PD1 enable anti-tumor responses against established HER2 BC. , 2020, , .		0
31	Clinical efficacy of intra-cavitary infusions of autologous dendritic cell/cytokine-induced killer cell products for the treatment of refractory malignant pleural effusions and ascites. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 3940-3952.	0.0	0
32	T-Scan: A Genome-wide Method for the Systematic Discovery of T Cell Epitopes. <i>Cell</i> , 2019, 178, 1016-1028.e13.	13.5	150
33	Impact of synchronized anti-PD-1 with Ad-CEA vaccination on inhibition of colon cancer growth. <i>Immunotherapy</i> , 2019, 11, 953-966.	1.0	8
34	Challenges with Novel Clinical Trial Designs: Master Protocols. <i>Clinical Cancer Research</i> , 2019, 25, 2049-2057.	3.2	35
35	Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology. <i>European Journal of Cancer</i> , 2019, 114, 128-136.	1.3	8
36	Functional CD3+CD8+PD1 \hat{r} T Cell Accumulation and PD-L1 Expression Increases During Tumor Invasion in DCIS of the Breast. <i>Clinical Breast Cancer</i> , 2019, 19, e617-e623.	1.1	8

#	ARTICLE	IF	CITATIONS
37	Prospective randomized comparative study on rivaroxaban and LMWH for prophylaxis of post-apheresis thrombosis in adoptive T cell immunotherapy cancer patients. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 505-511.	1.0	5
38	GEOGRAPHIC DISPARITIES IN LIFE EXPECTANCY AND MORTALITY IN THE U.S.. <i>Innovation in Aging</i> , 2019, 3, S427-S427.	0.0	0
39	A cancer rainbow mouse for visualizing the functional genomics of oncogenic clonal expansion. <i>Nature Communications</i> , 2019, 10, 5490.	5.8	31
40	Non-invasive diagnosis of endometriosis: using machine learning instead of the operating room. <i>Fertility and Sterility</i> , 2019, 112, e80.	0.5	2
41	Immune correlates of clinical benefit in a phase I study of hyperthermia with adoptive T cell immunotherapy in patients with solid tumors. <i>International Journal of Hyperthermia</i> , 2019, 36, 74-82.	1.1	21
42	Small Aperture Ultrasound Transducers for Intracavitary Tissue Ablation. , 2019, , .		0
43	Identification of novel triazole inhibitors of Wnt/ β 2-catenin signaling based on the Niclosamide chemotype. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 317-321.	1.0	7
44	Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study. <i>Clinical Cancer Research</i> , 2019, 25, 2725-2736.	3.2	50
45	Niclosamide-induced Wnt signaling inhibition in colorectal cancer is mediated by autophagy. <i>Biochemical Journal</i> , 2019, 476, 535-546.	1.7	44
46	Right Time and Place for IL12: Targeted Delivery Stimulates Immune Therapy. <i>Clinical Cancer Research</i> , 2019, 25, 9-11.	3.2	10
47	Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS). <i>Clinical and Translational Oncology</i> , 2019, 21, 721-728.	1.2	32
48	Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study. <i>Clinical Cancer Research</i> , 2019, 25, 1494-1504.	3.2	45
49	Abstract 4071: A novel combination therapy of high intensity focused ultrasound and PDL1 blockades against advanced breast cancer. , 2019, , .		1
50	CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis. <i>JCI Insight</i> , 2019, 4, .	2.3	77
51	Predictive significance of T cell subset changes during ex vivo generation of adoptive cellular therapy products for the treatment of advanced non-small cell lung cancer. <i>Oncology Letters</i> , 2019, 18, 5717-5724.	0.8	4
52	Abstract P2-09-16: CD8 T cells induced by novel alphaviral vector predict improved progression free survival in advanced HER2+ breast cancer patients. , 2019, , .		0
53	Effector T-cell cytolytic activity modules derived from CD3+ single cells from human primary triple-negative breast cancer (TNBC) in multiple solid tumors to predict response to immune checkpoint blockade therapy (ICB).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1073-1073.	0.8	0
54	Abstract 3731: A novel heat shock protein 90-targeted photosensitizer (HS-201) enables enhanced tumor-specific photodynamic therapy of inflammatory breast cancers. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
55	Abstract 3955: Tumor macrophage-mediated antibody dependent cell phagocytosis (ADCP) is the primary mechanism mediating HER2 mAb (Trastuzumab) anti-tumor responses which can be synergistically enhanced by CD47 innate immune checkpoint blockade. , 2019, , .		0
56	CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine. Cancer Chemotherapy and Pharmacology, 2018, 81, 365-372.	1.1	8
57	Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors. Oncoimmunology, 2018, 7, e1421891.	2.1	57
58	Circulating CD8 + CD28 $\hat{=}$ suppressor T cells tied to poorer prognosis among metastatic breast cancer patients receiving adoptive T-cell therapy: A cohort study. Cytotherapy, 2018, 20, 126-133.	0.3	20
59	Global Development of Anticancer Therapies for Rare Cancers, Pediatric Cancers, and Molecular Subtypes of Common Cancers. Journal of Global Oncology, 2018, 4, 1-11.	0.5	2
60	Health and the Environment in North Carolina. North Carolina Medical Journal, 2018, 79, 302-305.	0.1	0
61	The Impact of Coal-Powered Electrical Plants and Coal Ash Impoundments on the Health of Residential Communities. North Carolina Medical Journal, 2018, 79, 289-300.	0.1	37
62	Mortality and Health Outcomes in North Carolina Communities Located in Close Proximity to Hog Concentrated Animal Feeding Operations. North Carolina Medical Journal, 2018, 79, 278-288.	0.1	22
63	The Health Impacts of Environmental Policy. North Carolina Medical Journal, 2018, 79, 329-333.	0.1	2
64	Philanthropy Profile. North Carolina Medical Journal, 2018, 79, 337-338.	0.1	1
65	Identification of DK419, a potent inhibitor of Wnt/ β -catenin signaling and colorectal cancer growth. Bioorganic and Medicinal Chemistry, 2018, 26, 5435-5442.	1.4	10
66	Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers. Breast Cancer Research, 2018, 20, 90.	2.2	14
67	White paper on microbial anti-cancer therapy and prevention. , 2018, 6, 78.		108
68	Abstract A22: Augmentation of a novel adenoviral vaccine strategy by checkpoint inhibitors. , 2018, , .		1
69	Abstract B66: Targeted activation of innate immune adaptors MAVS and STING promotes antitumor responses in colorectal cancer models. , 2018, , .		0
70	A Fluorescent Hsp90 Probe Demonstrates the Unique Association between Extracellular Hsp90 and Malignancy <i>in Vivo</i> . ACS Chemical Biology, 2017, 12, 1047-1055.	1.6	40
71	Benzimidazole inhibitors from the Niclosamide chemotype inhibit Wnt/ β -catenin signaling with selectivity over effects on ATP homeostasis. Bioorganic and Medicinal Chemistry, 2017, 25, 1804-1816.	1.4	19
72	Inhibiting clathrin-mediated endocytosis of the leucine-rich G protein-coupled receptor-5 diminishes cell fitness. Journal of Biological Chemistry, 2017, 292, 7208-7222.	1.6	28

#	ARTICLE	IF	CITATIONS
73	Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy. <i>Onc Immunology</i> , 2017, 6, e1264563.	2.1	23
74	Bisphenol A activates EGFR and ERK promoting proliferation, tumor spheroid formation and resistance to EGFR pathway inhibition in estrogen receptor-negative inflammatory breast cancer cells. <i>Carcinogenesis</i> , 2017, 38, 252-260.	1.3	66
75	Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition. <i>Onc Immunology</i> , 2017, 6, e1315495.	2.1	17
76	Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study. <i>Clinical Cancer Research</i> , 2017, 23, 5066-5073.	3.2	62
77	<i>In Vivo</i> Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior. <i>Clinical Cancer Research</i> , 2017, 23, 7531-7542.	3.2	15
78	An unbiased in vivo functional genomics screening approach in mice identifies novel tumor cell-based regulators of immune rejection. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1529-1544.	2.0	12
79	Abstract P2-04-27: CTLA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer. , 2017, , .		1
80	Abstract B36: Modulating the tumor microenvironment to enhance cancer immunotherapy by inducing phosphatidylserine expression on the tumor surface. , 2017, , .		0
81	Abstract B04: Intralesional vaccination with Ad-MAVS alters the immunosuppressive tumor microenvironment and elicits robust anti-tumor immunity in non-immunogenic cancers. , 2017, , .		0
82	Abstract A38: Checkpoint blockade elicits unique T cell expansion to promote tumor regression. , 2017, , .		0
83	Abstract 4709: Induction of enhanced tumor-specific immunity by Hsp90 targeted photodynamic therapy (Hsp90-PDT) combined with immune checkpoint inhibition. , 2017, , .		0
84	Abstract 1859: Hsp90 targeted near infrared molecular imaging to detect mammographically occult invasive lobular breast cancer. , 2017, , .		0
85	Dormant breast cancer micrometastases reside in specific bone marrow niches that regulate their transit to and from bone. <i>Science Translational Medicine</i> , 2016, 8, 340ra73.	5.8	178
86	Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 2016, 17, 41.	1.3	33
87	Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. , 2016, 4, 15.		67
88	Preclinical Evaluation of ¹⁸ F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET. <i>Journal of Nuclear Medicine</i> , 2016, 57, 967-973.	2.8	68
89	Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged ≥ 45). <i>Clinical and Translational Oncology</i> , 2016, 18, 82-87.	1.2	34
90	X-Ray Psoralen Activated Cancer Therapy (X-PACT). <i>PLoS ONE</i> , 2016, 11, e0162078.	1.1	23

#	ARTICLE	IF	CITATIONS
91	Abstract P4-09-16: A monoclonal antibody with exceptional specificity across major breast cancer subtypes. , 2016, , .		0
92	Abstract 3417: Peripheral CD8+CD28-suppressive T lymphocytes act as a prognosticator among breast cancer patients with adoptive T-cell immunotherapy. , 2016, , .		0
93	The prognostic values of CYP2B6 genetic polymorphisms and metastatic sites for advanced breast cancer patients treated with docetaxel and thiotepa. Scientific Reports, 2015, 5, 16775.	1.6	8
94	Precision Cancer Immunotherapy. Journal of Immunotherapy, 2015, 38, 155-164.	1.2	25
95	Phase I study of alphaviral vector (AVX701) in colorectal cancer patients: comparison of immune responses in stage III and stage IV patients. , 2015, 3, .		14
96	Structure-activity studies of Wnt/ β -catenin inhibition in the Niclosamide chemotype: Identification of derivatives with improved drug exposure. Bioorganic and Medicinal Chemistry, 2015, 23, 5829-5838.	1.4	60
97	Lgr4 and Lgr5 drive the formation of long actin-rich cytoneme-like membrane protrusions. Journal of Cell Science, 2015, 128, 1230-40.	1.2	46
98	Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. Carcinogenesis, 2015, 36, S254-S296.	1.3	239
99	Cardiovascular comorbidities and survival of lung cancer patients: Medicare data based analysis. Lung Cancer, 2015, 88, 85-93.	0.9	84
100	Perhexiline promotes HER3 ablation through receptor internalization and inhibits tumor growth. Breast Cancer Research, 2015, 17, 20.	2.2	39
101	Regional Variation in Identified Cancer Care Needs of Early-career Oncologists in China, India, and Pakistan. Oncologist, 2015, 20, 532-538.	1.9	12
102	CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1. Cancer Immunology, Immunotherapy, 2015, 64, 677-688.	2.0	75
103	Checkpoint blockade in combination with cancer vaccines. Vaccine, 2015, 33, 7377-7385.	1.7	33
104	Breast Cancer Challenges and Screening in China: Lessons From Current Registry Data and Population Screening Studies. Oncologist, 2015, 20, 773-779.	1.9	44
105	Chemical compounds from anthropogenic environment and immune evasion mechanisms: potential interactions. Carcinogenesis, 2015, 36, S111-S127.	1.3	43
106	Effect of alphavirus vaccine encoding HER2 during concurrent anti-HER2 therapies on induction of oligoclonal T cell and antibody responses against HER2.. Journal of Clinical Oncology, 2015, 33, 3081-3081.	0.8	4
107	The prognostic value of peripheral CD4+CD25+ T lymphocytes among early stage and triple negative breast cancer patients receiving dendritic cells-cytokine induced killer cells infusion. Oncotarget, 2015, 6, 41350-41359.	0.8	14
108	Transformation of alkylating regimen of thiotepa into tepa determines the disease progression through GSTP1 gene polymorphism for metastatic breast cancer patients receiving thiotepa containing salvage chemotherapy. International Journal of Clinical Pharmacology and Therapeutics, 2015, 53, 914-922.	0.3	4

#	ARTICLE	IF	CITATIONS
109	Continuous DC-CIK Infusions Restore CD8+Cellular Immunity, Physical Activity and Improve Clinical Efficacy in Advanced Cancer Patients Unresponsive to Conventional Treatments. Asian Pacific Journal of Cancer Prevention, 2015, 16, 2419-2423.	0.5	9
110	Lgr4 and Lgr5 drive the formation of long actin-rich cytoneme-like membrane protrusions. Development (Cambridge), 2015, 142, e0705-e0705.	1.2	0
111	Abstract 3212: Metastatic breast cancer cell communication within a pro-dormancy bone marrow niche. , 2015, , .		0
112	Long-term dynamics of death rates of emphysema, asthma, and pneumonia and improving air quality. International Journal of COPD, 2014, 9, 613.	0.9	21
113	A review of the health impacts of barium from natural and anthropogenic exposure. Environmental Geochemistry and Health, 2014, 36, 797-814.	1.8	221
114	Overexpression of the EMT Driver Brachyury in Breast Carcinomas: Association With Poor Prognosis. Journal of the National Cancer Institute, 2014, 106, .	3.0	65
115	Designing effective vaccines for colorectal cancer. Immunotherapy, 2014, 6, 913-926.	1.0	3
116	Improved Tumor Targeting of Anti-HER2 Nanobody Through <i>N</i> -Succinimidyl 4-Guanidinomethyl-3-Iodobenzoate Radiolabeling. Journal of Nuclear Medicine, 2014, 55, 650-656.	2.8	77
117	A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype. Breast Cancer Research, 2014, 16, 407.	2.2	51
118	N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: Influence of isomeric substitution on radiolabeling and target cell residualization. Nuclear Medicine and Biology, 2014, 41, 802-812.	0.3	19
119	Immunotherapeutic treatment of metastatic colorectal cancer using ETBX-011.. Journal of Clinical Oncology, 2014, 32, 3093-3093.	0.8	3
120	Functional genomic screens and identification of signaling pathways in oxaliplatin-resistance in colorectal cancer.. Journal of Clinical Oncology, 2014, 32, 3611-3611.	0.8	0
121	Chemical Genomics Reveals JAK STAT Activation As a Mechanism of Resistance to HDAC Inhibitors in B Cell Lymphomas. Blood, 2014, 124, 271-271.	0.6	1
122	Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences. Clinical and Translational Oncology, 2013, 15, 780-788.	1.2	38
123	Specific genetic polymorphisms of IL10-592 AA and IL10-819 TT genotypes lead to the key role for inducing docetaxel-induced liver injury in breast cancer patients. Clinical and Translational Oncology, 2013, 15, 331-334.	1.2	20
124	Elevated level of peripheral CD8+CD28 ⁺ T lymphocytes are an independent predictor of progression-free survival in patients with metastatic breast cancer during the course of chemotherapy. Cancer Immunology, Immunotherapy, 2013, 62, 1123-1130.	2.0	54
125	Optical and Radioiodinated Tethered Hsp90 Inhibitors Reveal Selective Internalization of Ectopic Hsp90 in Malignant Breast Tumor Cells. Chemistry and Biology, 2013, 20, 1187-1197.	6.2	43
126	Modulation of Immune System Inhibitory Checkpoints in Colorectal Cancer. Current Colorectal Cancer Reports, 2013, 9, 391-397.	1.0	9

#	ARTICLE	IF	CITATIONS
127	Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF- α -independent mechanism. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 359-371.	1.1	107
128	Minimization of Heatwave Morbidity and Mortality. <i>American Journal of Preventive Medicine</i> , 2013, 44, 274-282.	1.6	146
129	Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1293-1301.	2.0	76
130	Small molecule modulators of Wnt/ β -catenin signaling. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 2187-2191.	1.0	23
131	A Randomized Phase II Study of Immunization With Dendritic Cells Modified With Poxvectors Encoding CEA and MUC1 Compared With the Same Poxvectors Plus GM-CSF for Resected Metastatic Colorectal Cancer. <i>Annals of Surgery</i> , 2013, 258, 879-886.	2.1	111
132	Constitutive Internalization of the Leucine-rich G Protein-coupled Receptor-5 (LGR5) to the Trans-Golgi Network. <i>Journal of Biological Chemistry</i> , 2013, 288, 10286-10297.	1.6	54
133	An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models. <i>Breast Cancer Research</i> , 2013, 15, R85.	2.2	120
134	Type III TGF- β 2 receptor downregulation generates an immunotolerant tumor microenvironment. <i>Journal of Clinical Investigation</i> , 2013, 123, 3925-3940.	3.9	94
135	Biomarkers and Correlative Endpoints for Immunotherapy Trials: What Can We Learn in Lung Cancer from Other Tumor Types?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, e287-e293.	1.8	12
136	Immunologic Targeting of FOXP3 in Inflammatory Breast Cancer Cells. <i>PLoS ONE</i> , 2013, 8, e53150.	1.1	16
137	Regulation of Hedgehog Signaling by Myc-Interacting Zinc Finger Protein 1, Miz1. <i>PLoS ONE</i> , 2013, 8, e63353.	1.1	7
138	A molecular profile of colorectal cancer to guide prognosis and therapy after resection of primary or metastatic disease.. <i>Journal of Clinical Oncology</i> , 2013, 31, 339-339.	0.8	1
139	Abstract 5681: Modulation of Wnt/ β -catenin signaling by niclosamide and related derivatives.. , 2013, , .		0
140	Abstract 5298: Two distinctive single nucleotide polymorphisms determine liver metastases responses to docetaxel plus thiotepa for metastatic breast cancer patients.. , 2013, , .		0
141	Abstract LB-164: Treatment of advanced stage colorectal cancer with ETBX-011 immunotherapeutic.. , 2013, , .		0
142	Biomarkers and Correlative Endpoints for Immunotherapy Trials: What Can We Learn in Lung Cancer from Other Tumor Types?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , e287-e293.	1.8	4
143	Abstract C86: Tethered Hsp90 inhibitors carrying optical or radioiodinated probes reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells.. , 2013, , .		0
144	The Insecticide Synergist Piperonyl Butoxide Inhibits Hedgehog Signaling: Assessing Chemical Risks. <i>Toxicological Sciences</i> , 2012, 128, 517-523.	1.4	30

#	ARTICLE	IF	CITATIONS
145	Characterization of an Oxaliplatin Sensitivity Predictor in a Preclinical Murine Model of Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1500-1509.	1.9	36
146	Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer. <i>Breast Cancer Research</i> , 2012, 14, R62.	2.2	145
147	Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells. <i>Breast Cancer Research</i> , 2012, 14, R89.	2.2	30
148	Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1941-1951.	2.0	22
149	101 Smac Mimetic Induces Apoptosis and Synergizes with TRAIL in Inflammatory Breast Cancer Cells in an IAP-Dependent and TNF- α -Independent Mechanism. <i>European Journal of Cancer</i> , 2012, 48, 32.	1.3	0
150	Depleting regulatory T cells with arginine-rich, cell-penetrating, peptide-conjugated morpholino oligomer targeting FOXP3 inhibits regulatory T-cell function. <i>Cancer Gene Therapy</i> , 2012, 19, 30-37.	2.2	11
151	Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines. <i>BMC Cancer</i> , 2012, 12, 402.	1.1	28
152	Identification of a novel Smoothed antagonist that potently suppresses Hedgehog signaling. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 6751-6757.	1.4	24
153	Histological and Molecular Evaluation of Patient-Derived Colorectal Cancer Explants. <i>PLoS ONE</i> , 2012, 7, e38422.	1.1	55
154	Recombinant human endostatin could eliminate the pro-angiogenesis priority of SP cells sorted from non-small cell lung cancer cells. <i>Clinical and Translational Oncology</i> , 2012, 14, 575-585.	1.2	11
155	Novel Recombinant Alphaviral and Adenoviral Vectors for Cancer Immunotherapy. <i>Seminars in Oncology</i> , 2012, 39, 305-310.	0.8	14
156	Non-genetic risk factors and predicting efficacy for docetaxel-induced liver injury among metastatic breast cancer patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1348-1352.	1.4	20
157	Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition. <i>Journal of Translational Medicine</i> , 2012, 10, 28.	1.8	77
158	ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 109-119.	1.1	54
159	Effect of the loss of the type III TGF β 2 receptor during tumor progression on tumor microenvironment: Preclinical development of TGF β 2 inhibition and TGF β 2-related biomarkers to enhance immunotherapy efficacy.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10563-10563.	0.8	3
160	Effect of the vaccine Ad5 [E1-, E2b-]-CEA(6D) on CEA-directed CMI responses in patients with advanced CEA-expressing malignancies in a phase I/II clinical trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2585-2585.	0.8	38
161	Discovering pathways in the tumor microenvironment important for recurrence-free survival in patients with colorectal liver metastasis.. <i>Journal of Clinical Oncology</i> , 2012, 30, 480-480.	0.8	9
162	Evaluating the Number of Stages in Development of Squamous Cell and Adenocarcinomas across Cancer Sites Using Human Population-Based Cancer Modeling. <i>PLoS ONE</i> , 2012, 7, e37430.	1.1	8

#	ARTICLE	IF	CITATIONS
163	Predictive and prognostic markers of recurrence after resection of primary or metastatic colorectal cancer.. Journal of Clinical Oncology, 2012, 30, 447-447.	0.8	0
164	Ad5 immunity after multiple safe, homologous immunizations against tumor-associated antigens with new recombinant Ad5 vector.. Journal of Clinical Oncology, 2012, 30, 85-85.	0.8	0
165	Abstract P4-08-07: Novel insight into the tumor "flare" phenomenon and lapatinib resistance. , 2012, , .		0
166	Increasing vaccine potency through exosome antigen targeting. Vaccine, 2011, 29, 9361-9367.	1.7	166
167	ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers. Clinical and Experimental Immunology, 2011, 163, 324-332.	1.1	36
168	Targeting GLI1 expression in human inflammatory breast cancer cells enhances apoptosis and attenuates migration. British Journal of Cancer, 2011, 104, 1575-1586.	2.9	48
169	Breast cancer as heterogeneous disease: contributing factors and carcinogenesis mechanisms. Breast Cancer Research and Treatment, 2011, 128, 483-493.	1.1	35
170	Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines. Immunologic Research, 2011, 49, 235-247.	1.3	11
171	Correlates of quality of life-related outcomes in breast cancer patients participating in the Pathfinders pilot study. Psycho-Oncology, 2011, 20, 559-564.	1.0	32
172	MHC class I-presented lung cancer-associated tumor antigens identified by immunoproteomics analysis are targets for cancer-specific T cell response. Journal of Proteomics, 2011, 74, 728-743.	1.2	18
173	Phase I Study Utilizing a Novel Antigen-Presenting Cell-Targeted Vaccine with Toll-like Receptor Stimulation to Induce Immunity to Self-antigens in Cancer Patients. Clinical Cancer Research, 2011, 17, 4844-4853.	3.2	129
174	Truncated ErbB2 Expressed in Tumor Cell Nuclei Contributes to Acquired Therapeutic Resistance to ErbB2 Kinase Inhibitors. Molecular Cancer Therapeutics, 2011, 10, 1367-1374.	1.9	45
175	HER2 Overexpression Elicits a Proinflammatory IL-6 Autocrine Signaling Loop That Is Critical for Tumorigenesis. Cancer Research, 2011, 71, 4380-4391.	0.4	116
176	MHC Class I-Presented Tumor Antigens Identified in Ovarian Cancer by Immunoproteomic Analysis Are Targets for T-Cell Responses against Breast and Ovarian Cancer. Clinical Cancer Research, 2011, 17, 3408-3419.	3.2	35
177	Need for Global Partnership in Cancer Care: Perceptions of Cancer Care Researchers Attending the 2010 Australia and Asia Pacific Clinical Oncology Research Development Workshop. Journal of Oncology Practice, 2011, 7, 324-329.	2.5	12
178	Antihelminth Compound Niclosamide Downregulates Wnt Signaling and Elicits Antitumor Responses in Tumors with Activating APC Mutations. Cancer Research, 2011, 71, 4172-4182.	0.4	239
179	Depletion of Human Regulatory T Cells. Methods in Molecular Biology, 2011, 707, 219-231.	0.4	16
180	P1-13-03: Zoledronic Acid Induces an Immune Response in Breast Cancer Patients through Stimulation of Central Memory and Effector Memory gamma/delta T-Cells.. , 2011, , .		2

#	ARTICLE	IF	CITATIONS
181	Survival rates among patients vaccinated following resection of colorectal cancer metastases in a phase II randomized study compared with contemporary controls.. Journal of Clinical Oncology, 2011, 29, 3557-3557.	0.8	8
182	Development of an assay to predict oxaliplatin sensitivity from formalin-fixed, paraffin-embedded (FFPE) colorectal cancer tissues.. Journal of Clinical Oncology, 2011, 29, 429-429.	0.8	0
183	Electronic Patient-Reported Data Capture as a Foundation of Rapid Learning Cancer Care. Medical Care, 2010, 48, S32-S38.	1.1	125
184	Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA. Cancer Immunology, Immunotherapy, 2010, 59, 1131-1135.	2.0	44
185	Phase 2 pilot study of Pathfinders: a psychosocial intervention for cancer patients. Supportive Care in Cancer, 2010, 18, 893-898.	1.0	27
186	Synergism from combined immunologic and pharmacologic inhibition of HER2 <i>in vivo</i> . International Journal of Cancer, 2010, 126, 2893-2903.	2.3	17
187	Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody. British Journal of Cancer, 2010, 102, 124-133.	2.9	74
188	X-Linked Inhibitor of Apoptosis Protein Inhibits Apoptosis in Inflammatory Breast Cancer Cells with Acquired Resistance to an ErbB1/2 Tyrosine Kinase Inhibitor. Molecular Cancer Therapeutics, 2010, 9, 1432-1442.	1.9	61
189	Ligand-Independent Toll-like Receptor Signals Generated by Ectopic Overexpression of MyD88 Generate Local and Systemic Antitumor Immunity. Cancer Research, 2010, 70, 7209-7220.	0.4	36
190	CSPG4 Protein as a New Target for the Antibody-Based Immunotherapy of Triple-Negative Breast Cancer. Journal of the National Cancer Institute, 2010, 102, 1496-1512.	3.0	148
191	Identification of select glucocorticoids as Smoothed agonists: Potential utility for regenerative medicine. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 9323-9328.	3.3	74
192	Immune Signatures Predict Prognosis in Localized Cancer. Cancer Investigation, 2010, 28, 765-773.	0.6	41
193	An Adenoviral Vaccine Encoding Full-Length Inactivated Human Her2 Exhibits Potent Immunogenicity and Enhanced Therapeutic Efficacy without Oncogenicity. Clinical Cancer Research, 2010, 16, 1466-1477.	3.2	24
194	Adenovirus vaccine immunotherapy targeting WT1-expressing tumors. Expert Opinion on Biological Therapy, 2010, 10, 875-883.	1.4	3
195	An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. Journal of Clinical Investigation, 2010, 120, 3234-3241.	3.9	98
196	Use of gene expression signatures to identify origin of primary and therapeutic strategies for patients with advanced solid tumors.. Journal of Clinical Oncology, 2010, 28, 10504-10504.	0.8	4
197	Effect of a novel recombinant alphaviral vector on tolerance to self-antigen in the setting of elevated regulatory T cells.. Journal of Clinical Oncology, 2010, 28, 2544-2544.	0.8	4
198	Abstract 5338: Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T cell killing mediated by CEA/CD3-bispecific T cell-engaging BiTE antibody. , 2010, , .		0

#	ARTICLE	IF	CITATIONS
199	Role of the type III TGF- β receptor in mediating immunosuppression during breast cancer progression.. Journal of Clinical Oncology, 2010, 28, 10577-10577.	0.8	0
200	Use of gene expression signatures to predict in vivo sensitivity of human metastatic colorectal cancer to chemotherapy and to identify novel drug combinations.. Journal of Clinical Oncology, 2010, 28, e14064-e14064.	0.8	0
201	Quantitative Trait Loci and Epistasis for Oat Winter Hardiness Component Traits. Crop Science, 2009, 49, 1989-1998.	0.8	17
202	Induction of Wilms' Tumor Protein (WT1)-Specific Antitumor Immunity Using a Truncated WT1-Expressing Adenovirus Vaccine. Clinical Cancer Research, 2009, 15, 2789-2796.	3.2	13
203	MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition. British Journal of Cancer, 2009, 101, 269-277.	2.9	23
204	Physiology and Therapeutics of Vascular Endothelial Growth Factor in Tumor Immunosuppression. Current Molecular Medicine, 2009, 9, 702-707.	0.6	50
205	Feasibility and Acceptability to Patients of a Longitudinal System for Evaluating Cancer-Related Symptoms and Quality of Life: Pilot Study of an e/Tablet Data-Collection System in Academic Oncology. Journal of Pain and Symptom Management, 2009, 37, 1027-1038.	0.6	126
206	Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity. Cancer Gene Therapy, 2009, 16, 673-682.	2.2	46
207	The Anti-Helminthic Niclosamide Inhibits Wnt/Frizzled1 Signaling. Biochemistry, 2009, 48, 10267-10274.	1.2	206
208	Immune Cells and the Tumor Microenvironment. , 2009, , 818-829.		0
209	The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunology, Immunotherapy, 2008, 57, 1115-1124.	2.0	271
210	Improving Health Care Efficiency and Quality Using Tablet Personal Computers to Collect Research Quality, Patient-Reported Data. Health Services Research, 2008, 43, 1975-1991.	1.0	128
211	Precision and linearity targets for validation of an IFN γ ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides. BMC Immunology, 2008, 9, 9.	0.9	67
212	Detailed analysis of cytomegalovirus (CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease. Cytotherapy, 2008, 10, 289-302.	0.3	12
213	Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression. Molecular Cancer Therapeutics, 2008, 7, 38-47.	1.9	62
214	Translational Research Working Group Developmental Pathway for Immune Response Modifiers. Clinical Cancer Research, 2008, 14, 5692-5699.	3.2	35
215	Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood, 2008, 112, 610-618.	0.6	282
216	E/Tablets to collect research-quality, patient-reported data. Journal of Clinical Oncology, 2008, 26, 17528-17528.	0.8	0

#	ARTICLE	IF	CITATIONS
217	Depletion of human regulatory T cells (Treg) and antigen-specific immune responses to cancer vaccines. <i>Journal of Clinical Oncology</i> , 2008, 26, 3010-3010.	0.8	0
218	Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 449-460.	1.4	106
219	Tumor Antigens. , 2007, , 17-31.		0
220	CPG-7909 (PF-3512676, ProMune [®]): toll-like receptor-9 agonist in cancer therapy. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 1257-1266.	1.4	51
221	Current Immunotherapeutic Strategies in Colon Cancer. <i>Surgical Oncology Clinics of North America</i> , 2007, 16, 873-900.	0.6	11
222	Investigation of HIFU-induced anti-tumor immunity in a murine tumor model. <i>Journal of Translational Medicine</i> , 2007, 5, 34.	1.8	161
223	Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2. <i>Journal of Translational Medicine</i> , 2007, 5, 42.	1.8	42
224	Dendritic cell vaccines. <i>Frontiers in Bioscience - Landmark</i> , 2007, 12, 4050.	3.0	38
225	Aging is associated with a rapid decline in frequency, alterations in subset composition, and enhanced Th2 response in CD1d-restricted NKT cells from human peripheral blood. <i>Experimental Gerontology</i> , 2007, 42, 719-732.	1.2	87
226	Immunotherapeutic targeting of Wilms' tumor protein. <i>Current Opinion in Molecular Therapeutics</i> , 2007, 9, 62-9.	2.8	11
227	Recent clinical progress in virus-based therapies for cancer. <i>Expert Opinion on Biological Therapy</i> , 2006, 6, 1123-1134.	1.4	12
228	Dendritic Cell-Based Immunotherapy. <i>International Reviews of Immunology</i> , 2006, 25, 377-413.	1.5	93
229	Role of natural killer cell function in dendritic cell-based vaccines. <i>Expert Review of Vaccines</i> , 2006, 5, 55-65.	2.0	16
230	NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 1122-1131.	2.0	63
231	Maximizing the retention of antigen specific lymphocyte function after cryopreservation. <i>Journal of Immunological Methods</i> , 2006, 308, 13-18.	0.6	135
232	Gene therapy for lung cancer. <i>Journal of Cellular Biochemistry</i> , 2006, 99, 1-22.	1.2	28
233	Investigation of HIFU-induced anti-tumor immunity in a murine tumor model. <i>AIP Conference Proceedings</i> , 2006, , .	0.3	3
234	Enumerating Antigen-Specific T-Cell Responses in Peripheral Blood. <i>Journal of Immunotherapy</i> , 2005, 28, 63-72.	1.2	70

#	ARTICLE	IF	CITATIONS
235	Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT. BMC Immunology, 2005, 6, 17.	0.9	96
236	Intracellular Cytokine Assays. , 2005, , 336-340.		0
237	The Development of Therapeutic and Preventive Vaccines for Gastric Cancer and Helicobacter pylori. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1883-1889.	1.1	10
238	Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs. International Immunology, 2005, 17, 1143-1155.	1.8	35
239	Phase I Study of Immunization with Dendritic Cells Modified with Fowlpox Encoding Carcinoembryonic Antigen and Costimulatory Molecules. Clinical Cancer Research, 2005, 11, 3017-3024.	3.2	127
240	Global Role of the Immune System in Identifying Cancer Initiation and Limiting Disease Progression. Journal of Clinical Oncology, 2005, 23, 8923-8925.	0.8	20
241	Recent developments in therapeutic cancer vaccines. Nature Clinical Practice Oncology, 2005, 2, 108-113.	4.3	48
242	Release of endogenous danger signals from HIFU-treated tumor cells and their stimulatory effects on APCs. Biochemical and Biophysical Research Communications, 2005, 335, 124-131.	1.0	95
243	A phase I study of dextran immunotherapy in patients with advanced non-small cell lung cancer. Journal of Translational Medicine, 2005, 3, 9.	1.8	870
244	Immune Monitoring. Cancer Treatment and Research, 2005, 123, 369-388.	0.2	7
245	How does the immune system attack cancer?. Current Problems in Surgery, 2004, 41, 15-132.	0.6	14
246	Accelerated Partial Breast Irradiation After Conservative Surgery for Breast Cancer. Annals of Surgery, 2004, 239, 338-351.	2.1	90
247	Effect of Cryopreservation on Assays of Antigen-Specific T Cells: Comparison of Tetramer, Cytokine Flow Cytometry, and ELISPOT. Journal of Immunotherapy, 2004, 27, S42.	1.2	0
248	Maximizing the Retention of Antigen Specific Lymphocyte Function after Cryopreservation. Journal of Immunotherapy, 2004, 27, S40.	1.2	0
249	Your Ad here: optimizing adenoviral vector-based vaccines. Blood, 2004, 104, 2612-2613.	0.6	0
250	Biology of the Cancer Vaccine Immune Response. , 2004, , 3-10.		1
251	Immunotherapy of surgical malignancies. Current Problems in Surgery, 2004, 41, 15-132.	0.6	5
252	Preparation of Peptide-Loaded Dendritic Cells for Cancer Immunotherapy. Molecular Biotechnology, 2003, 25, 95-100.	1.3	4

#	ARTICLE	IF	CITATIONS
253	Title is missing!. Journal of Neuro-Oncology, 2003, 64, 161-176.	1.4	6
254	The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. Journal of Neuro-Oncology, 2003, 64, 161-176.	1.4	33
255	Quantitating cellular immune responses to cancer vaccines. Seminars in Oncology, 2003, 30, 9-16.	0.8	35
256	HER2 Dendritic Cell Vaccines. Clinical Breast Cancer, 2003, 3, S164-S172.	1.1	26
257	Immunotherapy with Autologous, Human Dendritic Cells Transfected with Carcinoembryonic Antigen mRNA. Cancer Investigation, 2003, 21, 341-349.	0.6	159
258	CURRENT STATUS OF DENDRITIC CELL IMMUNOTHERAPY OF MALIGNANCIES. International Reviews of Immunology, 2003, 22, 255-281.	1.5	9
259	Tackling T-cell tumors. Blood, 2003, 102, 2313-2313.	0.6	2
260	Recent areas of development for dendritic cell vaccines. Cancer Chemotherapy and Biological Response Modifiers, 2003, 21, 339-350.	0.5	0
261	Dendritic Cell Recovery Following Nonmyeloablative Allogeneic Stem Cell Transplants. Journal of Hematotherapy and Stem Cell Research, 2002, 11, 659-668.	1.8	16
262	Immunoregulatory T cells in cancer immunotherapy. Expert Opinion on Biological Therapy, 2002, 2, 827-834.	1.4	48
263	Redirecting cytotoxic T lymphocyte responses with T-cell receptor transgenes. Expert Opinion on Biological Therapy, 2002, 2, 353-360.	1.4	8
264	Dendritic Cell-based Immunization for Cancer Therapy. Advances in Experimental Medicine and Biology, 2002, 465, 335-346.	0.8	9
265	Induction of Tumor-Specific Cytotoxic T Lymphocytes in Cancer Patients by Autologous Tumor RNA-Transfected Dendritic Cells. Annals of Surgery, 2002, 235, 540-549.	2.1	177
266	Dendritic Cell-Based Vaccines in Cancer. American Journal of Cancer, 2002, 1, 313-322.	0.4	0
267	Dendritic cell maturation in active immunotherapy strategies. Expert Opinion on Biological Therapy, 2002, 2, 35-43.	1.4	33
268	Current status of adoptive immunotherapy of malignancies. Expert Opinion on Biological Therapy, 2002, 2, 237-247.	1.4	19
269	Disparities in breast carcinoma treatment in Asian/Pacific Islander women. Cancer, 2002, 95, 2257-2259.	2.0	4
270	DNA and RNA Modified Dendritic Cell Vaccines. World Journal of Surgery, 2002, 26, 819-825.	0.8	14

#	ARTICLE	IF	CITATIONS
271	The Feasibility and Safety of Immunotherapy with Dendritic Cells Loaded with CEA mRNA Following Neoadjuvant Chemoradiotherapy and Resection of Pancreatic Cancer. <i>International Journal of Gastrointestinal Cancer</i> , 2002, 32, 1-6.	0.4	82
272	RNA-Transfected Dendritic Cells as Immunogens. , 2002, , 199-203.		0
273	Isolation and Culture of Dendritic Cells. , 2002, , 171-191.		0
274	Multiple signals are required for maturation of human dendritic cells mobilized in vivo with Flt3 ligand. <i>Journal of Leukocyte Biology</i> , 2002, 72, 546-53.	1.5	21
275	Direct detection of cellular immune responses to cancer vaccines. <i>Surgery</i> , 2001, 129, 248-254.	1.0	10
276	Surrogate Markers of Effective Anti-Tumor Immunity. <i>Annals of Surgical Oncology</i> , 2001, 8, 190-191.	0.7	4
277	Molecular Basis for Cell Tropism of CXCR4-Dependent Human Immunodeficiency Virus Type 1 Isolates. <i>Journal of Virology</i> , 2001, 75, 6776-6785.	1.5	86
278	Surrogate markers of response to cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2001, 1, 153-158.	1.4	7
279	Quantitating Therapeutically Relevant T-Cell Responses to Cancer Vaccines. <i>Critical Reviews in Immunology</i> , 2001, 21, 11.	1.0	15
280	Tumor-specific recognition of human myeloma cells by idiotype-induced CD8+ T cells. <i>Blood</i> , 2000, 96, 2828-2833.	0.6	106
281	A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon- γ treatment. <i>Blood</i> , 2000, 96, 3499-3504.	0.6	131
282	Preoperative Mobilization of Circulating Dendritic Cells by Flt3 Ligand Administration to Patients With Metastatic Colon Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 3883-3893.	0.8	120
283	Effect of Highly Active Antiretroviral Therapy and Thymic Transplantation on Immunoreconstitution in HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 403-413.	0.5	43
284	Optimizing Dendritic Cell Function by Genetic Modification. <i>Journal of the National Cancer Institute</i> , 2000, 92, 1198-1199.	3.0	2
285	Gene Therapy for Lung Cancer. <i>Clinical Lung Cancer</i> , 2000, 1, 218-226.	1.1	2
286	A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon- γ treatment. <i>Blood</i> , 2000, 96, 3499-3504.	0.6	5
287	Tumor-specific recognition of human myeloma cells by idiotype-induced CD8+ T cells. <i>Blood</i> , 2000, 96, 2828-2833.	0.6	7
288	A Comparative Study of the Generation of Dendritic Cells from Mobilized Peripheral Blood Progenitor Cells of Patients Undergoing High-Dose Chemotherapy. <i>Journal of Hematotherapy and Stem Cell Research</i> , 1999, 8, 577-584.	1.8	25

#	ARTICLE	IF	CITATIONS
289	Educational Review Cellular and Biological Therapies of Gastrointestinal Tumors: Overview of Clinical Trials. <i>Annals of Surgical Oncology</i> , 1999, 6, 218-223.	0.7	3
290	Carcinoembryonic Antigen Peptide-Pulsed Dendritic Cells in Patients with Metastatic Cancer. <i>Clinical Lung Cancer</i> , 1999, 1, 70-72.	1.1	0
291	Induction of carcinoembryonic antigen (cea)-specific cytotoxic t-lymphocyte responsesIn vitro using autologous dendritic cells loaded with cea peptide or cea rna in patients with metastatic malignancies expressing cea. , 1999, 82, 121-124.		151
292	The Role of IL-13 in the Generation of Dendritic Cells in Vitro. <i>Journal of Immunotherapy</i> , 1999, 22, 506-513.	1.2	38
293	Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. <i>Nature Biotechnology</i> , 1998, 16, 364-369.	9.4	383
294	Sylvester oâ€™halloran surgical scientific meeting. <i>Irish Journal of Medical Science</i> , 1998, 167, 1-16.	0.8	0
295	Royal academy of medicine in Ireland section of surgery. <i>Irish Journal of Medical Science</i> , 1998, 167, 101-104.	0.8	0
296	Immunotherapy of cancer with dendritic-cell-based vaccines. <i>Cancer Immunology, Immunotherapy</i> , 1998, 46, 82-87.	2.0	277
297	Dendritic cells improve the generation of Epstein-Barr virusâ€™specific cytotoxic T lymphocytes for the treatment of posttransplantation lymphoma. <i>Surgery</i> , 1998, 124, 171-176.	1.0	9
298	End points in the analysis of breast cancer survival: Relapse versus death from tumor. <i>Surgery</i> , 1998, 124, 197-202.	1.0	4
299	Dendritic cell-based approaches to cancer immunotherapy. <i>Expert Opinion on Investigational Drugs</i> , 1998, 7, 1617-1627.	1.9	4
300	AIDS-related malignancies. <i>Annals of Medicine</i> , 1998, 30, 323-344.	1.5	49
301	Gene Therapy and Pancreatic Cancer. <i>Surgical Oncology Clinics of North America</i> , 1998, 7, 217-249.	0.6	11
302	Transcriptional Targeting for Cancer Gene Therapy. <i>Surgical Oncology Clinics of North America</i> , 1998, 7, 565-574.	0.6	9
303	Use of Paravertebral Block Anesthesia in the Surgical Management of Breast Cancer. <i>Annals of Surgery</i> , 1998, 227, 496-501.	2.1	250
304	Active Immunization with Tumor Cells Transduced by a Novel AAV Plasmid-Based Gene Delivery System. <i>Journal of Immunotherapy</i> , 1997, 20, 26-27.	1.2	15
305	Active immunization using dendritic cells mixed with tumor cells inhibits the growth of primary breast cancer. <i>Surgery</i> , 1997, 122, 228-234.	1.0	22
306	Local recurrence of rectal cancer:evaluation with F-18 fluorodeoxyglucose PET imaging. <i>Abdominal Imaging</i> , 1997, 22, 332-337.	2.0	63

#	ARTICLE	IF	CITATIONS
307	Generation of Dendritic Cells In Vitro From Peripheral Blood Mononuclear Cells With Granulocyte-Macrophage-Colony-Stimulating Factor, Interleukin-4, and Tumor Necrosis Factor- α for Use in Cancer Immunotherapy. <i>Annals of Surgery</i> , 1997, 226, 6-16.	2.1	90
308	Active immunotherapy of pancreatic cancer with tumor cells genetically engineered to secrete multiple cytokines. <i>Surgery</i> , 1996, 120, 174-181.	1.0	26
309	Active immunotherapy with transiently transfected cytokine-secreting tumor cells inhibits breast cancer metastases in tumor-bearing animals. <i>Surgery</i> , 1996, 120, 265-273.	1.0	23
310	Paravertebral block for breast cancer surgery. <i>Canadian Journal of Anaesthesia</i> , 1996, 43, 858-861.	0.7	139
311	Laparoscopic Enteric Diversion. , 1996, , 185-191.		0
312	Gene Therapy in Surgery. <i>Annals of Surgery</i> , 1996, 223, 115.	2.1	1
313	Cytoreductive Surgery and Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis. <i>Annals of Surgery</i> , 1995, 221, 123.	2.1	1
314	Ambulatory Surgical Management of Breast Carcinoma Using Paravertebral Block. <i>Annals of Surgery</i> , 1995, 222, 19-26.	2.1	128
315	Gene modification of primary tumor cells for active immunotherapy of human breast and ovarian cancer. <i>European Journal of Cancer</i> , 1995, 31, S35.	1.3	0
316	Generation of Tumor-Specific T Lymphocytes for the Treatment of Posttransplant Lymphoma. <i>Circulation</i> , 1995, 92, 202-205.	1.6	12
317	Cytomegalovirus sialadenitis in patients with the acquired immunodeficiency syndrome: A potential diagnostic pitfall with fine-needle aspiration cytology. <i>Diagnostic Cytopathology</i> , 1994, 10, 169-172.	0.5	27
318	Irish society for gastroenterology. <i>Irish Journal of Medical Science</i> , 1994, 163, 37-47.	0.8	0
319	Sylvester O'Fallon surgical scientific meeting. <i>Irish Journal of Medical Science</i> , 1994, 163, 517-532.	0.8	1
320	Seventeenth Sir Peter Freyer memorial lecture and surgical symposium. <i>Irish Journal of Medical Science</i> , 1994, 163, 139-167.	0.8	0
321	T cells or active epstein-barr virus infection in the development of lymphoproliferative disease in human B cell-injected severe combined immunodeficient mice. <i>Annals of Surgical Oncology</i> , 1994, 1, 405-410.	0.7	14
322	Laparoscopic ileostomy and Colostomy. <i>Annals of Surgery</i> , 1994, 219, 317-322.	2.1	57
323	HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. <i>Cancer Research</i> , 1994, 54, 3387-90.	0.4	126
324	Retroviral gene transduction of circulating progenitor cells in patients with metastatic breast cancer. <i>Surgical Oncology</i> , 1993, 2, 1-6.	0.8	4

#	ARTICLE	IF	CITATIONS
325	Gene Delivery Systems in Surgery. Archives of Surgery, 1993, 128, 1197.	2.3	33
326	Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1. Science, 1992, 257, 535-537.	6.0	137
327	Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication.. Journal of Experimental Medicine, 1992, 176, 1197-1201.	4.2	204
328	Derivation of a biologically contained replication system for human immunodeficiency virus type 1.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 7678-7682.	3.3	29
329	Effects of cyclosporine on human B-cell lymphoma development in vivo. Surgical Oncology, 1992, 1, 79-86.	0.8	9
330	Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science, 1991, 253, 71-74.	6.0	970
331	Surgical Treatment of Chronic Pulmonary Embolism. Annual Review of Medicine, 1991, 42, 507-517.	5.0	4
332	Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects. Journal of Immunology, 1990, 144, 3375-84.	0.4	81
333	Minireview Anti-HIV-1 ADCC. AIDS Research and Human Retroviruses, 1989, 5, 557-563.	0.5	58
334	Utility of Doppler color flow imaging for identification of femoral arterial complications of cardiac catheterization. American Heart Journal, 1989, 117, 623-628.	1.2	66
335	HIV-1 GP120-mediated immune suppression and lymphocyte destruction in the absence of viral infection. Journal of Immunology, 1989, 142, 3091-7.	0.4	156
336	GP120 specific cellular cytotoxicity in HIV-1 seropositive individuals. Evidence for circulating CD16+ effector cells armed in vivo with cytophilic antibody. Journal of Immunology, 1989, 142, 1177-82.	0.4	65
337	Immunobiology of the External Envelope Viral Glycoprotein. , 1988, , 237-245.		0
338	CELLULAR ANTI-GP120 CYTOLYTIC REACTIVITIES IN HIV-1 SEROPOSITIVE INDIVIDUALS. Lancet, The, 1988, 331, 902-905.	6.3	122
339	Cellular Immune Response to Viral Peptides in Patients Exposed to HIV. AIDS Research and Human Retroviruses, 1988, 4, 259-267.	0.5	39
340	Characteristics of a Neutralizing Monoclonal Antibody to the HIV Envelope Glycoprotein. AIDS Research and Human Retroviruses, 1988, 4, 187-197.	0.5	164
341	Transmission of HIV by Antigen Presenting Cells During T-Cell Activation: Prevention by 3-azido-2-deoxythymidine. AIDS Research and Human Retroviruses, 1987, 3, 87-94.	0.5	14
342	Anti-GP 120 Antibodies from HIV Seropositive Individuals Mediate Broadly Reactive Anti-HIV ADCC. AIDS Research and Human Retroviruses, 1987, 3, 409-422.	0.5	144

#	ARTICLE	IF	CITATIONS
343	Humoral immune response to the entire human immunodeficiency virus envelope glycoprotein made in insect cells.. Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 6924-6928.	3.3	137
344	Interaction between the human T-cell lymphotropic virus type IIIB envelope glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion.. Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 5424-5428.	3.3	250
345	Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack.. Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 4601-4605.	3.3	229
346	Prospects for development of a vaccine against HIV-related disorders. Clinical Immunology Newsletter, 1987, 8, 49-52.	0.1	0
347	Prospects for Development of a Vaccine Against HTLV-III-Related Disorders. AIDS Research and Human Retroviruses, 1987, 3, 197-206.	0.5	14
348	ADMINISTRATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, AN INHIBITOR OF HTLV-III/LAV REPLICATION, TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX. Lancet, The, 1986, 327, 575-580.	6.3	754
349	Radiographic findings in pulmonary hypertension from unresolved embolism. American Journal of Roentgenology, 1985, 144, 681-686.	1.0	48
350	Voluntary Control of the Human Vestibulo-Ocular Reflex. Acta Oto-Laryngologica, 1984, 97, 1-6.	0.3	186